RxDoctor Payments Data

Megan Mavety, NP

Adult Health · Colorado Springs, CONPI 1164933578

Payments from drug & device makers

$438in general payments, 2019–2025

Across 17 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$124
  • Vanda Pharmaceuticals Inc.$112
  • AbbVie$45
  • AstraZeneca$44
  • Indivior Inc.$33
  • Sunovion Pharmaceuticals Inc.$26
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$438100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$438 in reported general payments places this provider in the 55th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$3,264
Medicare patients
34
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban49$66,690
TrulicityDulaglutide45$55,072
FarxigaDapagliflozin Propanediol37$38,453
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$26,068
OzempicSemaglutide14$22,920
TradjentaLinagliptin15$18,682
JardianceEmpagliflozin11$18,577
EliquisApixaban20$15,007
SymbicortBudesonide/Formoterol Fumarate22$10,844
Tresiba Flextouch U-100Insulin Degludec15$6,650
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$6,023
Breo ElliptaFluticasone/Vilanterol11$4,432
Albuterol Sulfate HfaAlbuterol Sulfate103$2,814
Gabapentin114$2,628
LantusInsulin Glargine,hum.Rec.Anlog20$2,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$23$66,69049 claims
Lilly USA, LLCTrulicity$12$55,07245 claims
AstraZenecaFarxiga, Symbicort$44$49,29759 claims
Boehringer IngelheimTradjenta, Jardiance$19$37,25926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 430 adult health providers in Colorado.

Other adult health in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →